Source link : https://newshealth.biz/health-news/oral-agent-for-diabetic-macular-edema-misses-mark-but-still-shows-promise/
DENVER — An investigational oral therapy for diabetic macular edema (DME) did not significantly affect retinal thickening in a placebo-controlled randomized trial. After 6 months of treatment, mean central subfield thickness (CST) decreased by 15 µm with the oral connexin 43 (Cx43) hemichannels inhibitor tonabersat as compared with a 5-µm increase in the placebo group. […]
The post Oral Agent for Diabetic Macular Edema Misses Mark but Still Shows Promise first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-08 20:23:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8